Korro to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Korro Bio (NASDAQ: KRRO) has announced its management team's participation in three major upcoming healthcare investor conferences in May and June 2025. CEO and President Ram Aiyar, Ph.D., will lead a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21. Both Dr. Aiyar and Chief Medical Officer Kemi Olugemo, M.D., FAAN, will present at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9.
The RBC fireside chat will be available via webcast on Korro's website, with a replay accessible for 30 days following the event.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences:
2025 RBC Capital Markets Global Healthcare Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET.
Jefferies Global Healthcare Conference
Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET.
Goldman Sachs 46th Annual Global Healthcare Conference
Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET.
A live webcast of the RBC fireside chat can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the fireside chat, a replay of the event will be available for 30 days.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Korro Bio (KRRO) presenting at the RBC Capital Markets Healthcare Conference 2025?
Who will represent Korro Bio (KRRO) at the upcoming investor conferences?
How can investors access Korro Bio's (KRRO) presentation at the RBC Healthcare Conference?
What time is Korro Bio's (KRRO) presentation at the Goldman Sachs Healthcare Conference?
